Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype
EMBO Mol Med. 2014 Apr;6(4):539-50. doi: 10.1002/emmm.201303214. Epub 2014 Feb 5. ABSTRACT The vascular endothelial growth factor (VEGF) pathway is a clinically validated antiangiogenic target for non-small cell lung cancer (NSCLC). However, some contradictory results have been reported on the biological effects of antiangiogenic drugs. In order to evaluate the efficacy of these drugs in […]








